Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Key Inclusion Criteria

Medically stable HIV-1 infected women who meet the following criteria:

- Completion of the Week 48 open-label extension (OLE) visit or any post Week 48 OLE
visits in Gilead-sponsored study GS-US-236-0128, or Completion of the Week 96 visit or
any post Week 96 visits in Gilead-sponsored study GS-US-292-0109 or completion of the
Week 144 visit or any post Week 144 visits in Gilead sponsored studies GS-US-292-0104
or GS-US-292-0111.

- Currently on a stable antiretroviral regimen consisting of E/C/F/TAF, E/C/F/TDF, or
ATV+RTV+FTC/TDF continuously for ≥ 12 consecutive weeks preceding the Screening visit

- Documented plasma HIV-1 RNA levels < 50 copies/mL for ≥ 12 weeks preceding the
Screening visit. After reaching HIV-1 RNA < 50 copies/mL, single values of HIV-1 RNA

≥ 50 copies/mL followed by re-suppression to < 50 copies/mL is allowed

- HIV-1 RNA <50 copies/mL at screening

- Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min (≥ 0.83 mL/sec) according to
the Cockcroft-Gault formula at the Screening visit

Note: Other protocol defined Inclusion/Exclusion criteria may apply.